Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17663464 | 0.92 | AAK1 (0.57) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL19253000 | 0.92 | AAK1 (0.57) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL17653364 | 0.86 | AAK1 (0.51) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL19252999 | 0.85 | AAK1 (0.50) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL17653145 | 0.82 | AAK1 (0.54) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL3979308 | 0.81 | MEN1 (0.36) | AAK1MEN1KMT2A | |
| SCHEMBL19252989 | 0.81 | AAK1 (0.48) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL19253020 | 0.78 | AAK1 (0.51) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL17663466 | 0.78 | AAK1 (0.51) | AAK1CTSLCTSBCTSSCTSK | |
| SCHEMBL17663442 | 0.78 | AAK1 (0.50) | AAK1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | AAK1, ULK1, NCK1 | AAK1 1/4885CTSL 4223/4885CTSB 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.